Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

GANX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Gain Therapeutics, Inc.NASDAQ: GANX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 42.23M shares rose 47.2% year over year, ahead of the +38.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 28.1% from the prior quarter. Over 3 fiscal years it compounded at +40.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +47.2% holds above the trailing-twelve-month pace of +38.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
42.23M+28.1% QoQ
Last fiscal yearDec 2025
32.97M+44.1% YoY
LTMMar 2026
35.13M+38.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.2%——
1 year+44.1%——
3-year CAGR+40.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
32.97M USD
Year-over-year change
+44.1%
4-year CAGR
+34.2%

Weighted Avg Shares vs competitors

How GANX compares with its peers on the latest reported figures

  • GANX's LTM Mar 2026 weighted avg shares of 35.13M shares is the 2nd highest of the 9 companies compared; the peer median is 29.44M shares.
  • Its year-over-year change of +38.4% is the 2nd highest of 8, against a peer median of +8.4%.
  • Over three fiscal years its annual growth of +40.5% compares with a peer median of +9.7%.
GANX Competitors Peer median
Weighted Avg Shares for GANX and competitors
Company Period LTM YoY 3-year CAGR
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
GANXGain Therapeutics, Inc.LTM Mar 202635.13M +38.4%+40.5%
ADAGAdagene Inc.LTM Jun 202435.12M —+2.9%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
XBITXBiotech Inc.LTM Mar 202630.49M +0.1%+0.1%
FBIOFortress Biotech, Inc.LTM Mar 202628.39M +34.1%+67.6%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
NTRBNutriband Inc.LTM Apr 202611.9M +8.4%+11.2%
ACETAdicet Bio, Inc.LTM Mar 20267.26M +28.8%+39.0%
Peer median (excluding GANX) 29.44M+8.4%+9.7%

Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue164.99K140.11K55.18K00
Cost of Revenue00000
Gross Profit164.99K140.11K55.18K00
Gross Margin100.0%100.0%100.0%——
Research & Development7.16M8.38M11.52M10.79M10.21M
Selling, General & Admin6.83M9.54M10.79M9.56M8.5M
Operating Expenses13.99M17.92M22.31M20.35M18.71M
Depreciation & Amortization15.48K64.17K83.58K84.07K94.05K
EBITDA(13.87M)(17.43M)(22.1M)(19.79M)(19.21M)
EBITDA Margin-8407.0%-12443.0%-40059.2%——
Operating Income(13.83M)(17.78M)(22.25M)(20.35M)(18.71M)
Operating Margin-8379.8%-12688.1%-40328.3%——
Interest Income12.5K375.36K494.23K357.1K244.39K
Interest Expense00000
Other Income / Expenses(60.43K)279.28K64.89K476.22K(589.28K)
Income Before Tax(13.89M)(17.5M)(22.19M)(19.87M)(19.3M)
Pre-Tax Margin-8416.4%-12488.8%-40210.7%——
Income Tax Expense4.01K92.98K79.28K536.82K861.12K
Net Income(13.89M)(17.59M)(22.27M)(20.41M)(20.16M)
Net Margin-8418.9%-12555.1%-40354.3%——
EPS (Basic)(1.37)(1.48)(1.71)(0.89)(0.61)
EPS (Diluted)(1.37)(1.48)(1.71)(0.89)(0.61)
Weighted Avg Shares10.17M11.88M13.01M22.88M32.97M
Weighted Avg Shares (Diluted)10.17M11.88M13.01M22.88M32.97M

Gain Therapeutics, Inc.

NASDAQ:GANX

Intrinsic Alpha fair value

Locked

Current Price

$1.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.